Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | FBP1 | P09467 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334047 | 0.85 | GSK3B (0.60) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL11663193 | 0.84 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL31415208 | 0.83 | PPARA (0.46) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL14254637 | 0.83 | PPARA (0.69) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL814827 | 0.83 | PPARA (0.69) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3900554 | 0.82 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL23582375 | 0.82 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3484192 | 0.82 | PPARA (0.59) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL8768736 | 0.81 | GSK3B (0.59) | PPARACYP1A2CYP3A4TSHRGSK3B | |
| SCHEMBL1154731 | 0.81 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697980-B | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4139286-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-23 | — | — | US | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-04 | — | — | US | disclosed |
| EP-4139286-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115697980-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021214019-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
| US-5627205-A | ANTILIPEMIC AGENTS AND ANTIOXIDANTS | ADIR ET COMPAGNIE (FR) | 1997-05-06 | — | — | US | disclosed |
| US-5512595-A | FOR SUPPRESSION OF MEMBRANE LIPID PEROXIDATION, ANTILIPEMIC AGENTS | ADIR ET COMPAGNIE (FR) | 1996-04-30 | — | — | US | disclosed |
| US-4105790-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139936-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | PPARA 1370/4885ABCB11 4447/4885CYP1A2 3829/4885 |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | PPARA 1370/4885ABCB11 4447/4885CYP1A2 3829/4885 |
| US-11964953-B2 | Substituted aminothiazoles as DGKzeta inhibitors for immune activation | DGKZ, DGKA, DGKG | PPARA 1370/4885ABCB11 4447/4885CYP1A2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.